Neilson Taylor, Li Zaibo, Minami Christina, Myers Sara P
Division of Surgical Oncology, Department of Surgery, The Ohio State University, Columbus, OH 43210, USA.
Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Cancers (Basel). 2025 Mar 23;17(7):1079. doi: 10.3390/cancers17071079.
Rare breast malignancies represent a challenge for treatment decision making given the lack of evidence-based guidelines. As a particularly uncommon tumor, adenoid cystic carcinomas are especially challenging. Although, histopathologically, they share the same tumor molecular profile as hormone receptor-negative and HER2 nonamplified carcinomas with aggressive physiology, adenoid cystic carcinomas generally have a favorable prognosis. Thus, there is evidence to suggest that more aggressive treatment regimens may not provide better therapeutic effects. In this review, we discuss ACCB with the goal of highlighting pathophysiology, clinical features, and treatment strategies. Existing data support consideration for adjuvant radiation with the omission of axillary staging and systemic therapies.
鉴于缺乏循证指南，罕见乳腺恶性肿瘤给治疗决策带来了挑战。腺样囊性癌作为一种极为罕见的肿瘤，尤其具有挑战性。尽管在组织病理学上，它们与具有侵袭性生理特征的激素受体阴性且HER2未扩增的癌具有相同的肿瘤分子特征，但腺样囊性癌总体预后良好。因此，有证据表明更积极的治疗方案可能无法带来更好的治疗效果。在本综述中，我们讨论腺样囊性癌，目的是突出其病理生理学、临床特征和治疗策略。现有数据支持考虑采用辅助放疗，同时省略腋窝分期和全身治疗。
